FDC Ltd Stock Price Today (NSE: FDC)
Fundamental Score
FDC Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
FDC Ltd share price today is ₹409.80, up +0.58% on NSE/BSE as of 31 July 2026. FDC Ltd (FDC) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.91K (Cr). The 52-week high for FDC share price is ₹527.80 and the 52-week low is ₹312.95. At a P/E ratio of 23.25x, FDC is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.46% and a debt-to-equity ratio of 0.01.
FDC Ltd Share Price Chart — NSE/BSE Historical Performance
FDC Ltd share price chart: -4.82% return over the past month. 52-week high ₹527.80, 52-week low ₹312.95.
FDC Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹408.00 | ₹413.20 | ₹406.00 | ₹409.80 | 1.38L (Cr) | |
| ₹412.00 | ₹415.00 | ₹405.35 | ₹407.45 | 1.03L (Cr) | |
| ₹409.00 | ₹416.00 | ₹408.50 | ₹414.30 | 55.10K (Cr) | |
| ₹417.10 | ₹417.95 | ₹404.90 | ₹407.45 | 86.92K (Cr) | |
| ₹417.00 | ₹419.80 | ₹411.60 | ₹417.10 | 60.67K (Cr) | |
| ₹399.50 | ₹416.05 | ₹397.05 | ₹412.95 | 96.73K (Cr) | |
| ₹410.30 | ₹411.90 | ₹399.90 | ₹401.25 | 1.23L (Cr) | |
| ₹414.40 | ₹419.10 | ₹410.35 | ₹413.25 | 92.43K (Cr) | |
| ₹421.40 | ₹426.00 | ₹415.50 | ₹417.90 | 74.13K (Cr) | |
| ₹422.00 | ₹422.60 | ₹413.55 | ₹420.10 | 86.85K (Cr) |
FDC Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹423.00 | ₹442.00 | ₹397.05 | ₹409.80 | -3.12% | |
| ₹408.00 | ₹432.00 | ₹373.25 | ₹423.85 | +3.88% | |
| ₹364.50 | ₹439.45 | ₹353.80 | ₹405.00 | +11.11% | |
| ₹325.50 | ₹376.30 | ₹320.50 | ₹364.45 | +11.97% | |
| ₹350.65 | ₹385.00 | ₹312.95 | ₹321.10 | -8.43% | |
| ₹376.90 | ₹399.50 | ₹350.35 | ₹356.65 | -5.37% | |
| ₹422.00 | ₹422.70 | ₹358.75 | ₹377.75 | -10.49% | |
| ₹414.45 | ₹433.45 | ₹403.55 | ₹423.10 | +2.09% | |
| ₹463.85 | ₹473.60 | ₹405.00 | ₹414.40 | -10.66% | |
| ₹446.20 | ₹476.40 | ₹429.15 | ₹460.65 | +3.24% | |
| ₹461.10 | ₹527.80 | ₹441.10 | ₹442.30 | -4.08% | |
| ₹475.95 | ₹496.80 | ₹455.20 | ₹457.75 | -3.82% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
FDC Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
FDC Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of FDC across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (16.67%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (15.89%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 23.25 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (167.39%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (18.89%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (80.24x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹499.62 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (69.66%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Weak Earnings Growth (1.67% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.93% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 8.69%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
FDC Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare FDC Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
FDC LtdFDC Ltd...Selected✓ FDC • 531599 | 60.4/100 | ₹409.80₹410 | ₹6906.42₹6906.42 | 23.25Average 23.3 Average | 12.46%Average 12.46% Average | 16.67%Good 16.67% Good | 0.01Excellent 0.0 Excellent | 0.93%Average 0.93% Average | 10.28%Good 10.28% Good | 1.18% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
FDC Ltd PE Ratio History
Historical price-to-earnings ratio for FDC — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹16.39 | ₹423.10 | 25.8x |
| FY 2024 | ₹1858.00 | ₹499.45 | 0.3x |
| FY 2023 | ₹11.67 | ₹396.45 | 34x |
| FY 2022 | ₹12.82 | ₹270.85 | 21.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
FDC Ltd Dividend History
Annual cash dividends paid by FDC — dividend yield 1.18%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹81.13 Cr |
| FY 2024 | ₹0.15 Cr |
| FY 2023 | ₹0.18 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
FDC Ltd Quarterly Performance
Latest quarterly metrics for FDC — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
18.89%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
167.39%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.28%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
0.93%
Compounded annual net profit growth over 5 years
FDC Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for FDC — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
FDC Ltd Financial Statements
Annual income statement, balance sheet and cash flow for FDC Ltd (FDC) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for FDC Ltd
About FDC (FDC Ltd)
FDC Ltd is a pioneering pharmaceutical company deeply rooted in the Indian subcontinent, with expanding influence across international markets. It's an organisation driven by innov...ation, continually researching and developing novel therapeutic solutions. Their core strength lies in crafting accessible, high-quality medications that address a diverse range of health needs. FDC is synonymous with robust manufacturing practices, ensuring adherence to the most stringent global regulatory standards. They are deeply committed to improving patient outcomes. FDC invests heavily in cutting-edge technology and advanced research facilities to stay at the forefront of pharmaceutical innovation. They have forged a reputation for reliability and efficacy among healthcare professionals and patients alike. The company's product portfolio is remarkably diverse, spanning across essential therapeutic categories. From tackling infectious diseases with potent anti-infectives to providing relief for digestive ailments and enhancing eye health with specialised ophthalmic treatments, FDC offers a comprehensive range of solutions. They are also significant players in addressing chronic conditions, providing effective cardiovascular and anti-diabetic therapies. With a keen eye on evolving health challenges, FDC develops innovative respiratory care products, supports women's health through gynaecological solutions, and offers specialised dermatological treatments. FDC also manufactures vital supplements and trusted analgesics to further support overall well-being and quality of life. FDC's commitment extends beyond manufacturing and distribution. They have cultivated strong relationships with healthcare providers, researchers, and regulatory bodies to foster collaboration and knowledge sharing. FDC dedicates resources to patient education programs, empowering individuals to make informed decisions about their health. Their dedication to ethical practices, environmental sustainability, and social responsibility are cornerstones of their business philosophy. FDC strives to be a trusted partner in global healthcare, dedicated to enhancing lives and providing accessible, effective pharmaceutical solutions to a global patient population.
Company Details
Key Leadership
Corporate Events
FDC Share Price: Frequently Asked Questions
What is the current share price of FDC Ltd?
FDC Ltd (FDC) trades at ₹409.80 on NSE and BSE. Market cap ₹6.91K (Cr). Educational data only.
What is the P/E ratio of FDC Ltd?
FDC Ltd has a P/E of 23.25x vs industry average 34.89x.
What is the Bull Run score for FDC Ltd?
FDC Ltd has a Bull Run score of 60.4/100 based on 25+ financial parameters.
Does FDC Ltd pay dividends?
FDC Ltd has a dividend yield of 1.18%. Past dividends don't guarantee future payments.
What is the ROE of FDC Ltd?
FDC Ltd has ROE of 12.46%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of FDC Ltd?
FDC Ltd has debt-to-equity of 0.01.
Is FDC Ltd a good investment?
Bull Run gives FDC Ltd a score of 60.4/100. This is not investment advice — consult a SEBI-registered advisor.